Assertio Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Assertio Therapeutics
ASRT Stock  USD 9.14  0.07  0.77%   
Analyzing historical trends in various income statement and balance sheet accounts from Assertio Therapeutics' financial statements helps investors evaluate the company's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Assertio Therapeutics' valuation are summarized below:
Gross Profit
89.9 M
Profit Margin
(0.21)
Market Capitalization
58.6 M
Enterprise Value Revenue
0.0375
Revenue
137.4 M
There are currently one hundred twenty fundamental signals for Assertio Therapeutics that can be evaluated and compared over time across rivals. All traders should validate Assertio Therapeutics' prevailing fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 1.2 B in 2026. Enterprise Value is likely to drop to about 1.2 B in 2026

Assertio Therapeutics Total Revenue

128.37 Million

Check Assertio Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Assertio Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 3.3 M, Total Revenue of 128.4 M or Gross Profit of 112.1 M, as well as many indicators such as Price To Sales Ratio of 10.89, Dividend Yield of 0.0 or PTB Ratio of 8.79. Assertio financial statements analysis is a perfect complement when working with Assertio Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Assertio Stock
Check out the analysis of Assertio Therapeutics Correlation against competitors.
For more information on how to buy Assertio Stock please use our How to Invest in Assertio Therapeutics guide.

Assertio Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets335.7 M327.4 M523 M
Very volatile
Short and Long Term Debt Total44 M46.3 M319.3 M
Slightly volatile
Total Current Liabilities74.2 M131.9 M117.3 M
Pretty Stable
Property Plant And Equipment Net1.9 M2 M5.9 M
Slightly volatile
Accounts Payable14.7 M16.9 M23.3 M
Pretty Stable
Non Current Assets Total89.8 M94.5 M316.4 M
Very volatile
Net Receivables65.3 M62.2 M45.7 M
Slightly volatile
Common Stock Shares Outstanding7.7 M7.3 M5.1 M
Very volatile
Liabilities And Stockholders Equity335.7 M327.4 M523 M
Very volatile
Other Current Assets10 M11.6 M15.6 M
Very volatile
Total Liabilities240.6 M188.2 M371.1 M
Very volatile
Total Current Assets136.2 M232.9 M200.2 M
Pretty Stable
Short Term Debt361.6 K380.6 K98.5 M
Slightly volatile
Cash79.3 M58.2 M117.7 M
Slightly volatile
Cash And Short Term Investments96 M115.1 M128.6 M
Slightly volatile
Non Current Liabilities Total53.5 M56.3 M247.2 M
Pretty Stable
Other Stockholder Equity959 M913.3 M394.6 M
Slightly volatile
Common Stock7.7 K8.1 K103.6 M
Slightly volatile
Other Assets1.091.1524.6 M
Very volatile
Property Plant Equipment962.5 K1 M5.7 M
Slightly volatile
Common Stock Total Equity11.1 K11.7 K106 M
Slightly volatile
Property Plant And Equipment Gross5.7 M5.9 M6.7 M
Pretty Stable
Other Liabilities29.7 M23.8 M33.9 M
Pretty Stable
Inventory46.3 M44.1 M16.3 M
Slightly volatile
Long Term Investments229.1 K241.2 K11.4 M
Slightly volatile
Non Current Liabilities Other4.7 M4.9 M26.6 M
Pretty Stable
Capital Surpluse552.7 M526.4 M266.9 M
Slightly volatile
Deferred Long Term Asset Charges39.7 M20.7 M36.4 M
Slightly volatile
Long Term Debt Total402.2 M244.1 M349.4 M
Very volatile
Short and Long Term Debt401.9 K423 K160.3 M
Slightly volatile
Net Invested Capital136.6 M143.8 M517.1 M
Slightly volatile
Capital Stock8.5 K10.3 K7.1 K
Slightly volatile

Assertio Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Revenue128.4 M143.7 M199.6 M
Pretty Stable
Gross Profit112.1 M98.6 M172.1 M
Pretty Stable
Other Operating Expenses145.2 M171.9 M218.2 M
Pretty Stable
Total Operating Expenses128.9 M126.7 M190.7 M
Pretty Stable
Depreciation And Amortization26.7 M29.7 M42.6 M
Pretty Stable
Selling General Administrative99.7 M86.4 M104.2 M
Pretty Stable
Selling And Marketing Expenses1.5 M1.6 M4.9 M
Slightly volatile
Interest Income2.8 M2.9 M30.1 M
Slightly volatile
Reconciled Depreciation45.8 M23.2 M74.4 M
Slightly volatile

Assertio Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow64.4 M84.5 M97.2 M
Very volatile
Depreciation26.9 M29.7 M43 M
Pretty Stable
Stock Based Compensation9.1 M5.8 M8.5 M
Very volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio10.8911.4668.9725
Slightly volatile
Days Sales Outstanding17318298.2849
Slightly volatile
Average Payables1.8 M1.7 M1.8 M
Slightly volatile
Stock Based Compensation To Revenue0.03530.03610.0442
Pretty Stable
Capex To Depreciation0.02430.02560.3372
Slightly volatile
EV To Sales10.811.3669.2445
Slightly volatile
Inventory Turnover0.880.922.3846
Pretty Stable
Days Of Inventory On Hand323410276
Very volatile
Sales General And Administrative To Revenue0.410.540.5258
Pretty Stable
Average Inventory2.6 M3.5 M3.7 M
Very volatile
Research And Ddevelopement To Revenue0.03340.03520.1379
Slightly volatile
Capex To Revenue0.00450.00470.0232
Slightly volatile
Cash Per Share0.90.957.2902
Slightly volatile
Intangibles To Total Assets0.410.250.4511
Pretty Stable
Current Ratio3.342.032.22
Pretty Stable
Receivables Turnover2.522.665.1031
Slightly volatile
Capex Per Share0.00970.01020.1938
Slightly volatile
Average Receivables528.6 K333.7 K329.1 K
Very volatile
Revenue Per Share1.121.1810.4696
Slightly volatile
Interest Debt Per Share0.390.4114.5074
Pretty Stable
Debt To Assets0.240.130.3393
Pretty Stable
Graham Number22.0514.2924.2023
Slightly volatile
Operating Cycle562592358
Slightly volatile
Long Term Debt To Capitalization0.340.220.4412
Pretty Stable
Total Debt To Capitalization0.340.220.4559
Pretty Stable
Quick Ratio3.231.652.0848
Pretty Stable
Net Income Per E B T1.240.91.8187
Pretty Stable
Cash Ratio0.480.511.901
Slightly volatile
Days Of Inventory Outstanding323410276
Very volatile
Days Of Sales Outstanding17318298.2849
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.140.9994
Pretty Stable
Fixed Asset Turnover69.0265.7353.6983
Slightly volatile
Debt Ratio0.240.130.3393
Pretty Stable
Price Sales Ratio10.8911.4668.9725
Slightly volatile
Asset Turnover0.290.390.4045
Pretty Stable
Gross Profit Margin1.30.790.9201
Pretty Stable

Assertio Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap1.2 B1.3 B5.3 B
Slightly volatile
Enterprise Value1.2 B1.3 B5.4 B
Slightly volatile

Assertio Fundamental Market Drivers

Forward Price Earnings12.1803
Cash And Short Term Investments100.1 M

Assertio Upcoming Events

13th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
13th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Assertio Therapeutics Financial Statements

Assertio Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Assertio Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Assertio Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Assertio Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue77.5 M42 M
Total Revenue143.7 M128.4 M
Cost Of Revenue45.1 M47.4 M
Stock Based Compensation To Revenue 0.04  0.04 
Sales General And Administrative To Revenue 0.54  0.41 
Research And Ddevelopement To Revenue 0.04  0.03 
Revenue Per Share 1.18  1.12 
Ebit Per Revenue(0.18)(0.19)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Assertio Stock Analysis

When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY